Tyra Biosciences, Inc.

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines targeting fibroblast growth factor receptor (FGFR) biology. The company leverages its SNÅP platform, which uses iterative molecular snapshots to predict genetic alterations and design therapies for oncology and genetically defined conditions. Its lead product candidate, FGFR3, is in clinical trials for metastatic urothelial carcinoma and solid tumors. Additionally, Tyra is developing TYRA-300 for skeletal conditions such as achondroplasia and hypochondroplasia, TYRA-200 for intrahepatic cholangiocarcinoma, and TYRA-430 for hepatocellular carcinoma. The company operates solely in the United States.

Tyra Biosciences is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol TYRA. Its shares are traded in U.S. dollars (USD), reflecting its primary listing in the United States. As a Nasdaq-listed company, it is subject to the exchange's listing standards and regulatory requirements. Investors can buy and sell TYRA shares through brokerage accounts that have access to U.S. equity markets.

Tyra Biosciences operates within the Healthcare sector, specifically in the Biotechnology industry. Biotechnology companies like Tyra focus on using biological processes and living organisms to develop medical treatments and diagnostics. As a clinical-stage biotech firm, Tyra is primarily engaged in research and development of precision medicines, with a particular emphasis on FGFR-targeted therapies for various cancers and genetic skeletal disorders. The company's work involves advanced drug design and clinical trials, which are characteristic of the biotechnology industry.

Tyra Biosciences is headquartered in Carlsbad, California, United States. The company was incorporated in 2018 and operates primarily within the U.S. market. Its research and development activities, including clinical trials for its product candidates, are conducted in the United States. While the company's focus is on developing therapies for global health conditions such as cancer and skeletal disorders, its current operations and market presence are centered in the U.S. There is no indication of international expansion or operations outside the United States based on available data.

Tyra Biosciences has a pipeline of precision medicine candidates targeting FGFR biology. Its lead candidate, FGFR3, is in clinical trials for metastatic urothelial carcinoma and solid tumors. The company is also developing TYRA-300 for skeletal conditions including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes. Additionally, TYRA-200 is being investigated for intrahepatic cholangiocarcinoma, a type of bile duct cancer, and TYRA-430 is in development for hepatocellular carcinoma, the most common form of liver cancer. These candidates are supported by the company's SNÅP platform, which enables iterative drug design based on genetic alterations.